{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"23"}]}],"title":"Treatment-emergent ADA positive (ADA Incidence)"},{"categories":[{"measurements":[{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"22"}]}],"title":"Treatment-induced ADA (Positive Post-baseline only)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"182"},{"groupId":"OG002","value":"102"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Number of participants with Anti-Drug Antibody (ADA) response to Tremelimumab. ADA positive post-baseline only was also referred to as treatment-induced ADA. Treatment-emergent ADA was defined as the sum of treatment-induced ADA and treatment-boosted ADA. Results are reported as number of participants with ADA responses to Tremelimumab for each indicated category.","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Tremelimumab ADA evaluable set includes all participants who received at least 1 dose of Tremelimumab and had non-missing baseline ADA and at least 1 non-missing post-baseline ADA results for Tremelimumab. T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"Samples were collected on Day 1 (Week 0), Week 12 and at 3 months after the last dose of tremelimumab. Assessed up to approximately 46 months after the first randomization.","title":"Presence of ADA for Tremelimumab","type":"SECONDARY","unitOfMeasure":"Participants"}